From: Coughlin, Daniel M. [dan.coughlin@walgreens.com]
Sent: 8/3/2010 1:05:17 PM
To: Ranick, Marcella F. [marcie.ranick@walgreens.com]
CC: Martin, Barbara A. [barb.martin@walgreens.com]; Murray Jr, Denman D. [denman.murray@walgreens.com]; Peters, Gary A. [gary.peters@walgreens.com]; Pinon, Dwayne A. [dwayne.pinon@walgreens.com]; Svihra, Edward J. [ed.svihra@walgreens.com]; Jacobs, Robert C. [robbie.jacobs@walgreens.com]; Gorman, Timothy J. [tim.gorman@walgreens.com]; Khanna, Rakesh [rakesh.khanna@walgreens.com]; Stahmann, Eric A. [eric.stahmann@walgreens.com]
Subject: Re: Suspicious Controlled Drug Orders
Attachments: image3.Gif; image4.Gif; image1.Gif; image2.Gif; image0.Gif

Travelling and unable to view. Some brief question though:

1. I recall the old paper report as being inches thick. This was replaced by same data on disc and eventually electronic tr ansmission. We were instructed in 1985 not to review or contact anyone on the data. Who from your group has been revi ewing the data collected for the past twenty-five years?

2. Doesn't the new program stop the release of suspicious quantity? Wouldn't this give your team more time or ability for whatever review would be performed? At present is anyone doing any review on what would be considered suspicious qu antities that are physically ordered and are releasing to stores?

----- Original Message -----
From: Marcie Ranick
Sent: 08/03/2010 12:38 PM CDT
To: Dan Coughlin
Cc: Barb Martin; Denman Murray; Gary Peters; Dwayne Pinon; Ed Svihra; Robbie Jacobs; Tim Gorman; Rakesh Khanna; Eric Stahmann
Subject: Re: Suspicious Controlled Drug Orders

Dan - in addition to the issues sent previously, the screens below show a discrepancy in the data which is compiled in the new ADR4 -
Threshold Violations program compared to the existing Suspicious Controlled Drug "Trigger" data, which is currently on M obius and is sent to the DEA on a monthly basis. From these screens, you can see that the new Threshold Violations rep ort does not match the data on Mobius Suspicious Controlled Drug Orders .

While it is understood that the new calculations will offer different results, it is apparent that the Mobius report will continue to list potential suspicious activity that is not addressed in the new ADR4 system. From this perspective, we believe that t he new system should be tested further and enhanced to provide broader coverage of controlled substance activity.

Although we will continue to explore the issues and results of the new system, we are not equipped to handle the 389+ pa ges of ADR4 data which are compiled nationwide each week. Is there a resource available in your department for data an alysis?

Please let me know if you have any questions,or would like to discuss. I would be happy to set up a meeting to discuss fu ll rollout, a date for the discontinuation of the monthly Mobius CD-
disc distribution, and subsequent monitoring and reporting from the new system.

Confidential - this report and its content is intended for restricted Walgreens internal distribution only.









DocumentDirect - jmobius_rdswin.walgreens.com: LD500U2b (08/02/2010 08:11:15 AM)]

File Edit View Script Policy Options Window Help

DATE 08/02/10 SUSPICIOUS CONTROL DRUG ORDERS FOR MONTH OF 07/2010
FOR WAREHOUSE 026
2370 E MAIN ST WOODLAND CA
WAREHOUSE DEA # RW0204026

WALGREEN STORE NO	DEA NO.	STORE ADDRESS		
05646	BW6761084	820 S HWY 160 PAHRUMP NV	89048	

WALGREEN ITEM NO.	DESCRIPTION:	UPC NUMBER	NDC NUMBER	AVE ORDER * DEA FACTOR =	TRIGGER
532538	MORPHINE SULF 20MG/ML (LAN)+ 30ML	30527142536	00527142536	5 3.0	15.0

DC	DATE ORDERED	QUANTITY	
026	05/13/10	11	
026	05/06/10	14	
	TOTAL ORDERED	25	166.66 %
026	04/29/10	4	
026	04/15/10	7	
026	04/08/10	5	
	TOTAL ORDERED	16	106.66 %

WALGREEN ITEM NO.	DESCRIPTION:	UPC NUMBER	NDC NUMBER	AVE ORDER * DEA FACTOR =	TRIGGER
564860	MORPHINE SULF 100MG CR+TAB(WT)100	30591351401	00591351401	3 3.0	9.0

DC	DATE ORDERED	QUANTITY	
026	07/07/10	4	
026	07/29/10	2	
026	07/22/10	5	
026	07/15/10	3	
026	07/01/10	2	
	TOTAL ORDERED	16	177.77 %
026	05/13/10	9	
026	05/06/10	7	
	TOTAL ORDERED	16	177.77 %
026	04/29/10	2	
026	04/22/10	1	
026	04/08/10	4	
026	04/01/10	6	
	TOTAL ORDERED	13	144.44 %
026	03/25/10	1	
026	03/11/10	1	
026	03/04/10	8	
	TOTAL ORDERED	10	111.11 %
026	02/25/10	7	
026	02/18/10	4	

Section Pg 573 of 1046

start



WAREHOUSE DEA # RW0204026

WALGREEN STORE NO	DEA NO.	STORE ADDRESS		
05646	BW6761084	820 S HWY 160 PAHRUMP NV	89048	

WALGREEN ITEM NO.	DESCRIPTION:	UPC NUMBER	NDC NUMBER	AVE ORDER * DEA FACTOR =	TRIGGER
682971	OXYCODONE HCL 30MG TAB (ACT)+ 100	35215221502	52152021502	8 3.0	24.0

DC	DATE ORDERED	QUANTITY	
	TOTAL ORDERED	46	191.66 %
026	03/25/10	5	
026	03/18/10	11	
026	03/11/10	11	
026	03/04/10	12	
	TOTAL ORDERED	39	162.50 %

WALGREEN ITEM NO.	DESCRIPTION:	UPC NUMBER	NDC NUMBER	AVE ORDER * DEA FACTOR =	TRIGGER
682972	OXYCODONE HCL 15MG TAB (ACT) +100	35215221402	52152021402	9 3.0	27.0

DC	DATE ORDERED	QUANTITY	
026	07/29/10	13	
026	07/22/10	5	
026	07/15/10	6	
026	07/08/10	21	
026	07/01/10	11	
	TOTAL ORDERED	56	207.40 %
026	05/11/10	9	
026	05/27/10	14	
026	05/20/10	28	
026	05/13/10	21	
026	05/06/10	15	
	TOTAL ORDERED	87	322.22 %
026	04/29/10	6	
026	04/22/10	3	
026	04/08/10	14	
026	04/01/10	13	
	TOTAL ORDERED	36	133.33 %
026	03/25/10	7	
026	03/18/10	3	
026	03/11/10	10	
026	03/04/10	12	
	TOTAL ORDERED	32	118.51 %
026	02/25/10	18	
026	02/18/10	9	

Marcie Ranick, RPH
Manager, Pharmacy Loss Prevention
847-964-4193
Fax 847-964-4966

Dan Coughlin/LOG/Walgreens

07/27/2010 12:51 PM

To Marcie Ranick/Corp/Walgreens@Walgreens, Barb Martin/Corp/Walgreens@Walgreens

cc Dwayne Pinon/Corp/Walgreens@Walgreens, Denman Murray/Corp/Walgreens@Walgreens, Robbie Jacobs/Corp/Walgreens@Walgreens, Tim Gorman/Corp/Walgreens@Walgreens, Ed Svihra/Corp/Walgreens@Walgreens

Subject Suspicious Control Drugs

The DEA asked us in 2009 to stop what was considered suspicious drug shipments to any of our stores. This would replace the current program where we would send the DEA diversion offices records on disks of what these same transactions were. I believe we have been testing the program that would stop orders considered suspicious in Las Vegas for some time.

Based on the results of Las Vegas, are we ready to roll out chain wide to meet the DEA requirements? From our division, we support the program if tests results have yielded the control of orders while not missing customers' script fills. Our concern is that the DEA could walk into a DC and discuss our inability to have the process in place after their request was made last year.

Any issues that would prevent presentation to the Market Pharmacy Directors and Executive group for pharmacies so they are aware of the changes before chain wide roll out?